Clinicopathologic Characterization of Hypocellular Acute Myeloid Leukemia (AML) Showed Fewer Genetic Abnormalities Involving Cell Proliferation and NPM1 When …
E Carlsen, NG Bailey, N Aggarwal… - American Journal of …, 2021 - academic.oup.com
Objectives Hypocellular acute myeloid leukemia (AML) is uncommon. Despite the
prognostic and therapeutic importance of mutational analysis, the mutational landscape of …
prognostic and therapeutic importance of mutational analysis, the mutational landscape of …
Timed alternate administration of decitabine and 5-azacytidine for cancer treatment
Y Saunthararajah, V Velcheti, K Kang, X Gu… - US Patent App. 17 …, 2022 - Google Patents
Provided herein are compositions, systems, kits, and methods for treating a patient with
cancer by alternate administration of decitabine and 5-azacytidine, or administration of …
cancer by alternate administration of decitabine and 5-azacytidine, or administration of …
[PDF][PDF] Response to:“Cytoplasmic dislocation of NPM1 and PU. 1 in NPM1-mutated leukemia is obscured by paraformaldehyde fixation”
Additional supporting information may be found online in the Supporting Information section
at the end of the article. Figure S1. Age-specific incidence rates of patients with chronic …
at the end of the article. Figure S1. Age-specific incidence rates of patients with chronic …
Deciphering the role of GPX4 in acute myeloid leukemia and identification of SMC4 as a possible novel therapeutic target in NPM1-mutated acute myeloid leukemia
T Ammer - 2023 - oparu.uni-ulm.de
AML is a form of acute myeloid leukemia with unsatisfactory survival rate. Therefore, novel
treatment options are needed. The role of ROS in leukemia and its impact on disease …
treatment options are needed. The role of ROS in leukemia and its impact on disease …
Analýza vlivu mutací v genu pro nukleofosmin na jeho interakční potenciál
M Šašinková - 2022 - dspace.cuni.cz
Nukleofosmin 1 (NPM1; nucleophosmin 1) se v buňce vyskytuje převážně v jadérku, ve
formě oligomerů tvořených skrze N-koncovou doménu (NTD; N-terminal domain), a jako …
formě oligomerů tvořených skrze N-koncovou doménu (NTD; N-terminal domain), a jako …
Identifying regulators of hepatic leukemia factor (HLF) expression in hematopoietic cells using a fluorescent reporter transgene
H Johnson - 2022 - papyrus.bib.umontreal.ca
Hepatic leukemia factor (HLF) is a transcription factor and one of the most selectively
expressed genes in human and mouse hematopoietic stem cells (HSCs). HLF identifies …
expressed genes in human and mouse hematopoietic stem cells (HSCs). HLF identifies …
Urothelial Gene Repression in Urothelial Cancers is Caused by Coactivator Deletions and Remedied by Inhibiting Corepressors
C Schuerger, S Biswas, KP Ng, L Cardone… - Available at SSRN … - papers.ssrn.com
Metastatic urothelial carcinoma (UC) confers 5-year survivals< 20%, encouraging
investigation of carcinogenic-mechanisms towards new treatments. UCs only partially …
investigation of carcinogenic-mechanisms towards new treatments. UCs only partially …
Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia
J Yao, M Zhao, J Wang, L Wei - Journal of Cancer …, 2020 - neoplasiaresearch.com
Acute myeloid leukemia (AML) is a clinical and genetic heterogeneous disease with a poor
prognosis. Recent advances in genomics and molecular biology have immensely improved …
prognosis. Recent advances in genomics and molecular biology have immensely improved …
[图书][B] Chronic interleukin-1 exposure triggers selective expansion of Cebpa-deficient multipotent hematopoietic progenitors
KC Higa - 2020 - search.proquest.com
The early events that drive hematologic disorders like clonal hematopoiesis,
myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia are …
myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia are …
[PDF][PDF] Using CRISPR/Cas9 Screens to Define Organizing Principles that Govern Drug Sensitivity in Acute Myeloid Leukemia
KH Lin - 2020 - dukespace.lib.duke.edu
In 2019, the cornerstone of the clinical management of acute myeloid leukemia (AML) is
chemotherapy. In fact, for the majority of patients diagnosed with AML, their best chance at …
chemotherapy. In fact, for the majority of patients diagnosed with AML, their best chance at …